Foundation Medicine Names Cindy Perettie as CEO
9 January 2019 - - US-based molecular information company Foundation Medicine, Inc. has appointed Cindy Perettie as chief executive officer, effective February 4, 2019, the company said.

Perettie will succeed Troy Cox. Perettie brings more than two decades of scientific and commercial experience with global biopharmaceutical organisations, most recently having served as a senior vice president in global oncology product strategy for Roche's Oncology unit.

She joins Foundation Medicine from Roche, where she's led one of the largest global oncology portfolios. Perettie has led several successful product launches in the US and abroad for Roche and Genentech across the oncology portfolio, including in breast cancer and hematology.

Perettie began her tenure at Genentech as a program team leader for bevacizumab, focused on lung cancer, breast cancer, gastrouterine cancer and melanoma.

She has held roles of increasing responsibility at Genentech since joining in 2004, including vice president of global regulatory operations and regional head of Europe, Middle East and Africa operations and global development.

Perettie took a hiatus from Genentech in 2012 to join Sarah Cannon Research Institute as president, Global Development Innovations.

There, she was responsible for leading and growing SCRI's contract research organization business globally, driving the execution of critical oncology clinical trials during her tenure.

Before joining Genentech, Perettie lead portfolio management at IVAX Pharmaceuticals and was the director of global program management at Élan Corp.

She started her career as a senior research associate at Johns Hopkins University, before taking on a research scientist associate director role at Chiron Corp.

Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer.